CAI Share Price Performance
US$0
-36.99 (-100.00%)
Price US$0
Fair ValueUS$27.00
Share Pricen/a
Narrative Update • Aug 10
Caris Life Sciences, Inc. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 32 Fair Values set on narratives written by author
CAI Community Narratives
AN
Fair Value
·Fair Value US$27 19.3% undervalued intrinsic discount
Whole Genome And MRD Adoption Will Support A Stronger Long Term Thesis
1users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
TA
Fair Value
·Fair Value US$74.17 70.6% undervalued intrinsic discount
The "Google Maps" of Cancer Biology – Data is the Moat
1users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value
·Fair Value US$22 0.9% undervalued intrinsic discount
Whole Genome Push Will Strain Margins Yet Could Eventually Support A Stronger Future
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
The "Google Maps" of Cancer Biology – Data is the Moat
Caris Life Sciences ($CAI) is the "Big Data" play of the biotech world. While companies like Recursion ($RXRX) use AI to find drugs, Caris uses AI to tell doctors which drug to use for a specific patient.Read more
Whole Genome Push Will Strain Margins Yet Could Eventually Support A Stronger Future
Caris Life Sciences is pushing deeper into whole-genome cancer testing and early detection, but that ambition may mean more spending and thinner profits before the payoff shows up. The big question is whether doctors, insurers, and drugmakers adopt these newer tests and data services fast enough to outweigh the extra investment.Read more
AN
US$22
0.9% undervalued intrinsic discount
Fair Value
Revenue
13.69% p.a.
Profit Margin
11.93%
Future PE
45.1x
Price in 2029
US$27.28
Whole Genome And MRD Adoption Will Support A Stronger Long Term Thesis
Caris Life Sciences is betting that more cancer doctors will rely on deeper genetic testing—and that follow‑up blood tests and earlier screening will create many more moments to test each patient. The upside comes with real hurdles, including insurance and government coverage, intense competition, and the chance the market shifts toward cheaper, simpler tests.Read more
AN
US$27
19.3% undervalued intrinsic discount
Fair Value
Profit Margin
11.38%
Future PE
58.92x
Price in 2029
US$33.33
Early Cancer Detection And MRD Leadership Will Deliver Outsized Long-Term Oncology Testing Upside
Caris Life Sciences is building one of the largest cancer testing data sets, and it’s trying to turn that scale into a bigger role in how doctors find and treat cancer. The upside hinges on whether new tests that spot cancer earlier and track it after treatment can win broad insurance coverage before rivals and pushback on pricing slows the momentum.Read more
AN
US$36
39.4% undervalued intrinsic discount
Fair Value
Profit Margin
20.54%
Future PE
39.33x
Price in 2029
US$44.44
Trending Discussion
No trending discussion available.
Recently Updated Narratives
TA
Caris Life Sciences ($CAI): The "Big Data" Juggernaut Just Delivered a 94% Growth Surprise
Fair Value: US$74.17 70.6% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CAI: Q2 Execution And Buybacks Will Support Balanced Future Prospects
Fair Value: US$22 0.9% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CAI: Early Detection Sequencing Platform Will Drive Future Upside Potential
Fair Value: US$27 19.3% undervalued intrinsic discount
8 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Caris Life Sciences, Inc. Key Details
About CAI
- Founded
- 2008
- Employees
- 1846
- CEO
- WebsiteView website
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company’s molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
